HS
ELVN icon

HighVista Strategies’s Enliven Therapeutics ELVN Stock Holding History

HighVista Strategies’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7M Buy
137,866
+64,764
+89% +$2.75M 1.6% 14
2026
Q1 		$2.87M Sell
73,102
-9,434
-11% -$261K 0.79% 41
2025
Q4 		$1.27M Sell
82,536
-176,599
-68% -$3.52M 0.33% 83
2025
Q3 		$5.3M Buy
259,135
+117,619
+83% +$2.37M 1.3% 18
2025
Q2 		$2.84M Buy
141,516
+29,057
+26% +$550K 1.04% 21
2025
Q1 		$2.21M Hold
112,459
– – 0.85% 28
2024
Q4 		$2.53M Hold
112,459
– – 0.94% 26
2024
Q3 		$2.87M Sell
112,459
-7,330
-6% -$170K 0.99% 32
2024
Q2 		$2.8M Sell
119,789
-7,065
-6% -$149K 1.02% 26
2024
Q1 		$2.23M Sell
126,854
-10,387
-8% -$159K 0.8% 43
2023
Q4 		$1.9M Buy
137,241
+12,654
+10% +$155K 0.69% 48
2023
Q3 		$1.7M Buy
124,587
+3,514
+3% +$59.2K 0.79% 39
2023
Q2 		$2.47M Buy
+121,073
New +$2.45M 1.13% 30

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

HighVista Strategies's ELVN Position: Q2 2026 in Review

HighVista Strategies increased its Enliven Therapeutics (ELVN) stake by 89% in Q2 2026, buying an estimated $2.75M and bringing the position to 137,866 shares worth $7M. The position accounts for 1.6% of the portfolio, ranked #14.

HighVista Strategies first reported a position in ELVN in Q2 2023 and has held it in 13 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • HighVista Strategies held 137,866 shares of Enliven Therapeutics worth $7M as of Q2 2026.
  • HighVista Strategies bought 64,764 Enliven Therapeutics shares in Q2 2026, an estimated $2.75M.
  • Enliven Therapeutics made up 1.6% of HighVista Strategies's portfolio in Q2 2026, its #14 holding.
  • HighVista Strategies first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.